

Report of the meeting to review the Paediatric Antituberculosis Drug Optimization priority list



World Health
Organization

Report of the meeting to review the Paediatric Antituberculosis Drug Optimization priority list

Report of the meeting to review the paediatric antituberculosis drug optimization priority list

ISBN 978-92-4-002215-7 (electronic version)

ISBN 978-92-4-002216-4 (print version)

© **World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. Report of the meeting to review the paediatric antituberculosis drug optimization priority list. Geneva: World Health Organization; 2021. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

CONTENTS

Acknowledgements.....	iv
Abbreviations	v
GLOSSARY	vii
Executive summary	ix
1. Background.....	1
2. Summary of the presentations.....	1
2.1. Opening session.....	2
2.2. Session 1 – Rifapentine	4
2.3. Session 2 – Second-line medicines	7
2.4. Session 3 – First-line medicines	10
2.5. Session 4 – The current TB drug development pipeline and emerging research priorities for children	12
3. Updated PADO-TB priority list.....	14
4. Next steps.....	16
Annex 1. Priorities agreed by PADO-TB1 (February 2019)	17
Annex 2. Agenda of the virtual review of PADO-TB1 PRIORITIES	18
Annex 3. List of participants	20
Annex 4. The landscape of RPT for TB prevention and treatment in children – summary of the rationale for an update to the WHO PQ EOI	23
References	26

ACKNOWLEDGEMENTS

The writing and overall coordination of this meeting report was led by Tiziana Masini, Sabine Verkuijl and Annemieke Brands at the World Health Organization (WHO), under the supervision of Dr Tereza Kasaeva, Director, WHO Global Tuberculosis Programme (WHO GTB).

Other contributors

Martina Casenghi (Elizabeth Glaser Pediatric AIDS Foundation, Switzerland), Anthony Garcia-Prats (Wisconsin University, United States of America [USA]), Anneke Hesselning (Stellenbosch University, South Africa), Lindsay McKenna (Treatment Action Group, USA), Linh Nguyen (WHO GTB, Switzerland), Kendra Radtke (University of California San Francisco [UCSF]), Rada Savic (UCSF) and Kerri Viney (WHO GTB, Switzerland).

ABBREVIATIONS

1HP	1 month of daily isoniazid plus rifapentine
3HP	3 months of weekly isoniazid plus rifapentine
3HR	3 months of daily isoniazid plus rifampicin
4R	4 months of daily rifampicin monotherapy
6/9H	6–9 months of daily isoniazid monotherapy
Bdq	bedaquiline
Cfz	clofazimine
Dlm	delamanid
DR-TB	drug-resistant tuberculosis
DS-TB	drug-susceptible tuberculosis
DT	dispersible tablet
DTG	dolutegravir
E, EMB	ethambutol
EFV	efavirenz
EML	Essential Medicines List
EOI	expression of interest
FDC	fixed-dose combination (medicines)
FQ	fluoroquinolone
GAP-f	Global Accelerator for Paediatric formulations
GDF	Stop TB Partnership's Global Drug Facility
Global Fund	Global Fund to Fight AIDS, Tuberculosis and Malaria
GTB	Global TB Programme
H, INH	isoniazid
HIV	human immunodeficiency virus
Lzd	linezolid
M, Mfx	moxifloxacin
MDR-TB	multidrug-resistant tuberculosis
PADO	Paediatric Antituberculosis Drug Optimization
Pa	pretomanid

PD	pharmacodynamics
PK	pharmacokinetics
PQ	prequalification (of medicines)
R, Rif	rifampicin
R, RPT	rifapentine
RR-TB	rifampicin-resistant tuberculosis
TB	tuberculosis
TPMAT	Tuberculosis Procurement and Market Shaping Action Team
TPT	tuberculosis preventive treatment
US FDA	United States Food and Drug Administration
WAZ	weight-for-age z-scores
WHO	World Health Organization

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23960

